News Search Results
May 15, 2025, 14:00 ET SparX Biopharmaceutical Corp Announces Research Agreement with Mitsubishi Tanabe Pharma America to Advance Novel Antibody-Drug Conjugates
May 15, 2025 /PRNewswire/ -- SparX Biopharmaceutical Corp ("SparX"), a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today announced the signing of a research agreement with Mitsubishi
More news about: SparX Biopharmaceutical
May 15, 2025, 11:16 ET AI In Life Science Analytics Market Size to reach $3.6 billion, Globally, by 2030 - Exclusive Research by The Research Insights
requirements as they happen. By Based on End Use, the AI In Life science Analytics Market is divided into, Medical Devices, Pharmaceutical, Biotechnology, and Others. In 2023 the pharmaceutical sector became the market leader with 46.3% of total revenue share. Among industries adopting AI analytics,
More news about: The Research Insights
May 15, 2025, 10:31 ET Abzena Announces Establishment of Scientific Advisory Board to Support Innovation Strategy
CEO/ Operations Head of Pharmaceutical Technical Solutions, Inc. (PTSI). Providing technical oversight and client representative support to the Biotechnology, Gene Therapy, Viral Vector, Cell Therapy, T-CELL, CAR T, mRNA, 503a/ 503b Compounding, and Vaccine Pharmaceutical
More news about: Abzena
May 15, 2025, 09:30 ET Nationwide to Introduce Kadance Precision Health Management Program
designed to drive proactive care and long-term impact. Kadance and its subsidiary, Kailos Genetics, LLC, are based at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. For more information, visit
More news about: Kadance, Inc.
May 15, 2025, 09:00 ET Orna Therapeutics Presents New Preclinical Data Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases at the American Society of Gene and Cell Therapy Annual Meeting
Mass., May 15, 2025 /PRNewswire/ -- Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced
More news about: Orna Therapeutics
May 15, 2025, 08:02 ET RyboDyn Expands Strategic Cancer Immunotherapy Collaboration with Moffitt Cancer Center
SAN DIEGO, May 15, 2025 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, today announced the expansion of its strategic collaboration with Moffitt
More news about: RyboDyn
May 15, 2025, 07:30 ET Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may
More news about: Elevation Oncology
May 15, 2025, 05:45 ET Investors in Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
May 15, 2025, 01:22 ET 2025 ASGCT | Immunofoco's In Vivo CAR-T Technology Platform Debuts with Groundbreaking Innovations
https://www.prnewswire.com/news-releases/2025-asgct--immunofocos-in-vivo-car-t-technology-platform-debuts-with-groundbreaking-innovations-302456246.html SOURCE Immunofoco Biotechnology
More news about: Immunofoco Biotechnology
May 15, 2025, 01:04 ET Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions
collaborators, and strategic investors to expand diagnostic access and co-develop market-specific solutions. About Anbio Biotechnology Anbio Biotechnology is a globally oriented IVD company focused on empowering healthcare professionals through innovative diagnostic solutions. Its portfolio
More news about: Anbio Biotechnology
May 14, 2025, 17:31 ET Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market | DelveInsight
companies, including Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences,
More news about: DelveInsight Business Research, LLP
May 14, 2025, 17:27 ET Aspen Neuroscience to Present at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Louisiana. The annual meeting, the largest gathering of cell and gene therapy professionals, hosts a global audience of attendees from academia, the biotechnology and pharmaceutical industries, government, and non-profit patient foundations. "We are excited to be part of this meeting, which covers the
More news about: Aspen Neuroscience, Inc.
May 14, 2025, 17:27 ET GordonMD Global Investments® Welcomes Cellarity's Appointment of Ted Myles as Chief Executive Officer, Strengthening Leadership Amid Scientific and Program Progress
working with Ted and the team as they develop more treatments to meet wide-ranging patient needs." "Cellarity is a powerhouse of AI-powered biotechnology," said Ted Myles, CEO of Cellarity. "Its end-to-end platform and bold scientific vision are unmatched. I'm excited
More news about: GordonMD Global Investments®
May 14, 2025, 16:05 ET Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
May 14, 2025, 16:05 ET MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March
More news about: MetaVia Inc.
May 14, 2025, 16:01 ET Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
$ 29,603 About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
May 14, 2025, 11:00 ET Stephen Wright, MD, Joins BRC Therapeutics as Development Advisor
in the field and continues to have major impact on innovation in drug development." Dr. Wright has over 30 years of experience in the biotechnology and pharmaceuticals industry, having played a key role in the development of Epidiolex®, the first FDA-approved prescription cannabidiol
More news about: Biopharmaceutical Research Company
May 14, 2025, 10:46 ET Minimalist Routine, Maximalist Results: GRAES Launches with 8-in-1 Night Cream to Combat "Beauty Burnout"
friends and family, I could see their eyes light up in recognition. That's why I started GRAES," said Martin. Drawing on her background in biotechnology and immunology, Martin spent years researching ingredients and identifying over 350 known irritants and sensitizers—none of which are included in
More news about: GRAES
May 14, 2025, 10:09 ET 25th Global Family Office Investment Summit in Dubai Co-Hosted by Anthony Ritossa and Lives Amplified Global Institution of World Leaders Celebrates a Decade of Impact and Innovation
transformation in just five years. Exponential advancements in artificial intelligence, immersive computing, decentralized finance, and biotechnology are redefining the way we live, work, and invest. Unlimited Awesome is building the next generation of innovators and change-makers." "I
More news about: Ritossa Family Office
May 14, 2025, 10:01 ET CRISPR Market worth US$5.47 billion by 2030 with 11.2% CAGR | MarketsandMarkets™
academia, biotechnology, and the pharmaceutical industry. By Based on end users, the CRISPR services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. Among these, pharmaceutical & biotechnology companies
More news about: MarketsandMarkets
May 14, 2025, 09:30 ET Rgenta Therapeutics Announces Presentation of Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, at the European Hematology Association (EHA) 2025 Congress
Mass. , May 14, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics
May 14, 2025, 09:00 ET Nortian Secures $41M to Launch U.S. Manufacturing Operations & Lead the High-Protein Ecosystem Revolution
[email protected] About Nortian Founded in 2024, Nortian is a U.S.-based biotechnology company pioneering the production of ultra-pure collagen from hide through a proprietary, vertically integrated process. Designed for use across
More news about: Nortian
May 14, 2025, 08:55 ET AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA
More news about: AbbVie
May 14, 2025, 07:30 ET Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
May 14, 2025, 07:13 ET FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
correlate with neurocognitive manifestations of the disorder. About REGENXBIO Inc.REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development
More news about: NS Pharma, Inc.